Eribulin Mesylate CAS:441045-17-6, a synthetic analog of halichondrin B, is a highly potent microtubule-targeting agent with unique functional properties. Its distinct mechanism of action involves the inhibition of microtubule growth, leading to cell cycle arrest and apoptosis. As a member of the halichondrin class, Eribulin Mesylate exhibits a highly specific binding affinity for tubulin, offering promising potential in pharmaceutical research and development.
Introduction to the application:
Eribulin Mesylate is extensively studied for its applications in oncology, primarily as a chemotherapeutic agent for the treatment of advanced or metastatic cancers. Its efficacy has been demonstrated in clinical trials, resulting in FDA approval for the management of metastatic breast cancer and liposarcoma. With its unique mechanism and proven effectiveness, Eribulin Mesylate continues to be a significant focus in pharmaceutical research, aiming to expand its therapeutic indications and improve patient outcomes.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.